Pfizer Inc. (NYSE:PFE) Plans Quarterly Dividend of $0.42

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, April 24th, RTT News reports. Stockholders of record on Friday, May 10th will be given a dividend of 0.42 per share by the biopharmaceutical company on Friday, June 14th. This represents a $1.68 annualized dividend and a dividend yield of 6.65%. The ex-dividend date of this dividend is Thursday, May 9th.

Pfizer has raised its dividend by an average of 2.6% annually over the last three years and has increased its dividend every year for the last 15 years. Pfizer has a payout ratio of 61.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.77 per share next year, which means the company should continue to be able to cover its $1.68 annual dividend with an expected future payout ratio of 60.6%.

Pfizer Price Performance

NYSE PFE opened at $25.26 on Friday. The business’s fifty day moving average price is $27.01 and its 200-day moving average price is $28.48. The stock has a market capitalization of $143.04 billion, a price-to-earnings ratio of 70.17, a PEG ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer has a 1-year low of $25.23 and a 1-year high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. On average, equities analysts predict that Pfizer will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.